コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 , dextran, gelatin, hydroxyethyl starch, and hypertonic saline).
2 nse after an intraperitoneal injection of 1M hypertonic saline.
3 s that may be up-regulated with edema and/or hypertonic saline.
4 IOP produced by episcleral vein injection of hypertonic saline.
5 ients treated with continuous IV infusion 3% hypertonic saline.
6 urface, which was significantly augmented by hypertonic saline.
7 intracranial disease should be treated with hypertonic saline.
8 eater than in wild-type mice pretreated with hypertonic saline.
9 This response was completely abrogated by hypertonic saline.
10 nt until recently were water restriction and hypertonic saline.
11 ot small bowel organ water was diminished by hypertonic saline.
12 exia is stimulated by chronic consumption of hypertonic saline.
13 tation (equal salt), and MV-HTN with 4 mL/kg hypertonic saline.
14 ithelial Na channels, and resuscitation with hypertonic saline.
15 S) and resuscitated with Ringer's lactate or hypertonic saline.
16 , 4 [3-6] to 7 [6-9]; p = 0.008) after 23.4% hypertonic saline.
17 was seen with and without administration of hypertonic saline.
18 ay rhDNase (2.5 mg), and twice-daily 5 mL 7% hypertonic saline.
19 of 0.9% saline or various concentrations of hypertonic saline.
20 lene glycol and at least one of the doses of hypertonic saline.
21 an albumin, 3.5% hypertonic saline, and 7.5% hypertonic saline.
22 ombination of hyperventilation, mannitol and hypertonic saline.
23 washed with excess chondroitin 6-sulphate or hypertonic saline.
24 ently with nebulized racemic epinephrine and hypertonic saline.
25 CH selected the nebulization technique using hypertonic saline.
26 Continuous IV infusion 3% hypertonic saline.
27 dverse effects theoretically associated with hypertonic saline.
28 es adopted the approach of giving a bolus of hypertonic saline.
29 uced in rats by episcleral vein injection of hypertonic saline.
30 with continuous intravenous infusion of 7.5% hypertonic saline (0.5 mL/hr; acetate/chloride, 50:50) a
32 on-directed therapies (mannitol, 56% vs 21%; hypertonic saline, 14% vs 7%; hypothermia, 24% vs 10%; p
34 greater increase measured using 23.4% or 30% hypertonic saline (23.4%, 365.0 +/- 8.8 mosm/L, p < .05
35 Group 2 (n = 15) received standard care and hypertonic saline (30%) via infusion to maintain serum s
38 normal saline; 2-TBI, normal saline; 3-TBI, hypertonic saline; 4-TBI, 100mM NaLac, 5-TBI, 500 mM NaL
39 y assigned to receive treatment with inhaled hypertonic saline (5 ml of 7 percent sodium chloride) fo
40 mOsm/L) as was water content of small bowel (hypertonic saline, 69.1+/-5.8%; normal saline, 74.7+/-0.
45 water content was significantly reduced with hypertonic saline (73.9+/-1.1%; 359+/-10 mOsm/L) (mean+/
46 (75.6 +/- 1.3%, 339 +/- 16 mOsm/L), and 7.5% hypertonic saline (74.9 +/- 0.7%, 360 +/- 23 mOsm/L) sig
47 nitol (74.4 +/- 1.2%, 352 +/- 15 mOsm/L), 5% hypertonic saline (75.6 +/- 1.3%, 339 +/- 16 mOsm/L), an
48 .8%; normal saline, 74.7+/-0.71%) and brain (hypertonic saline, 78.1+/-0.87%; normal saline, 79.2+/-0
49 sphere of wildtype mice was attenuated after hypertonic saline (79.9% +/- 0.5%; mean +/- SEM) but not
51 ine had no effect on the postischemic edema (hypertonic saline: 80.3% +/- 0.7%; 0.9% saline: 80.3% +/
52 ular action principle in mechanistic detail: Hypertonic saline acts via metalloproteinase 9 (MMP9).
54 ined at least within high normal limits, but hypertonic saline administered to 145-155 mmol/L may be
55 The use of therapeutic interventions such as hypertonic saline administration and decompressive crani
59 e lung injury in wild-type mice treated with hypertonic saline after cecal ligation and puncture was
61 nt isotonic and hypotonic challenges, and to hypertonic saline, an effective therapy for mucus hydrat
62 pression in the MnPN after administration of hypertonic saline and Ang-II in both spontaneously sleep
63 to compare the effects of equimolar doses of hypertonic saline and dextran solution (HSD, Rescueflow)
64 ere treated with different concentrations of hypertonic saline and endotoxin of Escherichia coli O111
65 ng advantageous resuscitative fluids such as hypertonic saline and hemoglobin-based oxygen carriers a
66 arch has demonstrated an association between hypertonic saline and hyperchloremia, limited data exist
70 d determined the effects of osmotherapy with hypertonic saline and mannitol on total lung water, as w
71 outcome was hospital billing for parenteral hypertonic saline and mannitol use, by day of service.
73 rmonatremic controls; concurrent infusion of hypertonic saline and myoinositol increased brain myoino
74 ormonatremic animals, concurrent infusion of hypertonic saline and myoinositol increased brain myoino
75 mber of studies show the cellular effects of hypertonic saline and no studies, to our knowledge, have
76 fibrillary acidic protein immunostaining in hypertonic saline and normal saline treated rats, and un
77 nificantly improved in patients treated with hypertonic saline and placebo, whereas the residual volu
78 active treatment group (n = 158) received 7% hypertonic saline and the control group (n = 163) receiv
80 were randomized to control (with and without hypertonic saline) and mesenteric venous hypertension wi
81 s, chronic dehydration (produced by drinking hypertonic saline) and sustained hypovolemia (produced b
82 s: 4 followed a nebulization technique using hypertonic saline, and 2 followed a chest or abdomen mas
83 3% (2,069 of 6,238) of the patients received hypertonic saline, and 40% (2,500 of 6,238) received man
85 % with hypertonic saline/dextran, 75.7% with hypertonic saline, and 75.1% with normal saline (P = .88
86 addition, vogue methods such as hypothermia, hypertonic saline, and aggressive surgical decompression
87 compared the effectiveness of daily rhDNase, hypertonic saline, and alternate-day rhDNase in children
89 GABAergic neurones in spontaneously sleeping hypertonic saline- and Ang-II-treated rats versus respec
90 y reactivity to NK A (NKA), substance P, and hypertonic saline; and to examine HIB before and after c
91 emic encephalopathy and early treatment with hypertonic saline are critical for successful outcomes.
92 studied whether these protective effects of hypertonic saline are related to improved gammadeltaT ce
96 ries of experiments (n = 32), treatment with hypertonic saline attenuated postischemic blood-brain ba
97 via the perivascular pool of aquaporin-4, 2) hypertonic saline attenuates blood-brain barrier disrupt
98 ical role in water egress from brain; and 3) hypertonic saline attenuates blood-brain barrier disrupt
99 We have previously shown that treatment with hypertonic saline attenuates cerebral edema associated w
100 tested the hypothesis that osmotherapy with hypertonic saline attenuates cerebral edema following ex
102 ly higher (88%) than in animals treated with hypertonic saline before cecal ligation and puncture (50
103 of human polymorphonuclear neutrophils with hypertonic saline before stimulation with formyl methion
107 he novel pharmacologic agent dexanabinol; b) hypertonic saline; c) mild hypothermia; and d) decompres
111 to 116 traits assessed through blood tests, hypertonic saline challenge tests, questionnaires, and s
112 injury was attenuated by both amiloride and hypertonic saline, combined administration of amiloride
113 ars with cystic fibrosis, the use of inhaled hypertonic saline compared with isotonic saline did not
115 nd ventricular volumes increased after 23.4% hypertonic saline, consistent with a reduction in brain
116 We investigated the hypothesis that bolus hypertonic saline decreases cerebral edema in severe hep
119 e hypothesis that two 4-mL x kg(-1) doses of hypertonic saline dextran (HSD; 7.5% NaCl/6% dextran-70)
120 being brought into clinical use, especially hypertonic saline dextran, haemoglobin-based oxygen carr
121 ons of patients with severe TBI (GOSE </=4) (hypertonic saline/dextran vs normal saline: 53.7% vs 51.
122 e 250-mL bolus of 7.5% saline/6% dextran 70 (hypertonic saline/dextran), 7.5% saline (hypertonic sali
124 suscitation with either hypertonic saline or hypertonic saline/dextran, compared with normal saline,
125 oinositol or infusion of myoinositol without hypertonic saline did not increase brain myoinositol lev
128 of intracerebral hematoma, a single dose of hypertonic saline effectively reduces the intraparenchym
132 se data demonstrate that 1) osmotherapy with hypertonic saline exerts antiedema effects via the periv
135 ne, combined administration of amiloride and hypertonic saline failed to further protect the gut.
139 We hypothesized that aerosolized inhaled hypertonic saline given at the onset of resuscitation wi
143 ed in an increase in serum osmolarity in all hypertonic saline groups (p < .05 vs. normal saline), wi
147 shown promise in poor grade patients, while hypertonic saline has shown better intracranial pressure
148 have shown a potential benefit of nebulized hypertonic saline; however, its effect in the emergency
149 irway dehydration could be reversed, we used hypertonic saline (HS) as an osmolyte to rehydrate ASL.
151 urrent evidence is unclear about the role of hypertonic saline (HS) for the acute treatment of bronch
153 n, have found a limited benefit of nebulized hypertonic saline (HS) treatment in the pediatric emerge
154 produced by a rehydrating treatment based on hypertonic saline (HS), a current CF clinical treatment.
158 atients received 4 mL of 3% sodium chloride (hypertonic saline [HS group]) or 0.9% sodium chloride (n
161 ysiologic differences in neural responses to hypertonic saline (HTS) were investigated in subjects wi
162 randomized to receive either 7.2% saline/6% hypertonic saline hydroxyethyl starch (4 mL/kg) or vehic
163 y resuscitation, which was not influenced by hypertonic saline hydroxyethyl starch administration.
164 ing results in other models of brain injury, hypertonic saline hydroxyethyl starch failed to improve
166 ocampal CA1 and neocortex with no effects of hypertonic saline hydroxyethyl starch on neuronal surviv
172 er A3 receptors may diminish the efficacy of hypertonic saline in a mouse model of acute lung injury.
175 to account for the effects of amiloride and hypertonic saline in CF lung disease, indicating the nee
176 a indicate the clinical benefit of nebulized hypertonic saline in cystic fibrosis lung disease, with
179 e, this study focused on the hypothesis that hypertonic saline-induced improvements in histological o
180 ing a sustained experimental pain challenge (hypertonic saline infused in the masseter muscle) with a
183 ratio of Mean Expiratory Flow after 240s of hypertonic saline inhalation with respect to the age- an
184 (Forced Expiratory Flow Volume after 240s of hypertonic saline inhalation; p = 4.81*10(-4)) and CD14
186 Unilateral elevation of IOP was produced by hypertonic saline injection into an episcleral vein in 2
196 1.0%; contralateral, 79.7 +/- 0.6%) and 7.5% hypertonic saline (ipsilateral, 82.3 +/- 1.3%; contralat
206 miloride suppresses the beneficial effect of hypertonic saline, it has been previously concluded that
207 miloride and small-volume resuscitation with hypertonic saline may be a strategy worthy of further ev
208 igible trials, but our findings suggest that hypertonic saline may be superior to the current standar
209 in water content with continuous infusion of hypertonic saline may have therapeutic implication in th
213 20), 5% hypertonic saline (n = 20), or 7.5% hypertonic saline (n = 18) as a chloride/acetate mixture
214 (n = 21), 20% mannitol (2 g/Kg) (n = 20), 5% hypertonic saline (n = 20), or 7.5% hypertonic saline (n
217 the effects of different tonicity of infused hypertonic saline on cerebral, lung, and small bowel wat
222 ed in a blinded randomized fashion with 7.5% hypertonic saline or 0.9% normal saline in a 8-mL/kg int
223 34), alpha-Syn(-/-) mice treated with either hypertonic saline or 0.9% saline had smaller infarct vol
226 mic shock, initial resuscitation with either hypertonic saline or hypertonic saline/dextran, compared
229 uous infusion only for 48 hrs of either 7.5% hypertonic saline or normal saline (1 mL/kg/hr) (n=10 ea
230 uous intravenous infusion (1 mL/kg/hr) of 5% hypertonic saline or normal saline, respectively (n=10 e
231 umin) or crystalloids (n = 1443; isotonic or hypertonic saline or Ringer lactate solution) for all fl
232 ore fluid in response to either subcutaneous hypertonic saline or water deprivation with partial rehy
233 70 (hypertonic saline/dextran), 7.5% saline (hypertonic saline), or 0.9% saline (normal saline) initi
234 us intravenous infusion of normal saline, 3% hypertonic saline, or 7.5% hypertonic saline for 24, 48,
239 luid vs. 230 +/- 19 pg/mL, shock vs. shock + hypertonic saline, p = .009) and pretreatment with a mat
241 patients with cystic fibrosis, inhalation of hypertonic saline produced a sustained acceleration of m
246 syx(4) mutant animals have severely impaired hypertonic saline response in vivo, an assay indicating
249 A3 antagonists could improve the efficacy of hypertonic saline resuscitation by reducing side effects
250 l A3 receptors expression determines whether hypertonic saline resuscitation inhibits or aggravates p
253 he effect of A3 receptors on the efficacy of hypertonic saline resuscitation was assessed in A3 recep
256 a were induced unilaterally, by injection of hypertonic saline solution, episcleral vein cauterizatio
257 emorrhagic shock and multiple-system trauma, hypertonic saline solutions are increasingly being used
261 ed concentrations of menthol, capsaicin, and hypertonic saline that evoked comparable levels of nocif
262 postocclusion) was robustly attenuated with hypertonic saline therapy (ipsilateral, 81.59 +/- 0.52%;
263 cardiopulmonary resuscitation: 1) continuous hypertonic saline therapy maintained to achieve serum os
266 Interventions: Intravenous infusion of 3% hypertonic saline to increase serum sodium to levels nec
270 de values should be monitored closely during hypertonic saline treatment as moderate elevations may i
271 brain water is responsive to continuous 7.5% hypertonic saline treatment begun at 24 hrs postischemia
272 c arrest/cardiopulmonary resuscitation, 7.5% hypertonic saline treatment did not attenuate water cont
273 f water content of extracerebral organs with hypertonic saline treatment may have therapeutic implica
276 ceptor expression and degranulation, whereas hypertonic saline-treatment after formyl methionyl-leucy
278 ly, mortality in wild-type mice with delayed hypertonic saline-treatment was significantly higher (88
279 comes Consortium multicenter out-of-hospital Hypertonic Saline Trial in patients with Glasgow Coma Sc
281 ating that there is a therapeutic window for hypertonic saline use after traumatic brain injury.
283 %; difference, 2.2% [95% CI, -4.5% to 9.0%]; hypertonic saline vs normal saline: 54.3% vs 51.5%; diff
284 urther increased to 31.8 +/- 3.1% when 20 mM hypertonic saline was added with lipopolysaccharide.
292 this study, we tested the hypothesis that a) hypertonic saline when given as an intravenous bolus and
293 , and brain water content is attenuated with hypertonic saline when serum osmolality is >350 mOsm/L w
294 amage was induced by episcleral injection of hypertonic saline, which caused sclerosis and blockade o
295 ence interval, 1.6 to 11.7; P=0.02), whereas hypertonic saline with amiloride did not improve FEV1 (m
296 mal rats respond to intravenous infusions of hypertonic saline with gradual, linear increases in disc
298 ing treatment with continuous IV infusion 3% hypertonic saline, with moderate hyperchloremia independ
299 onatremic and hyponatremic rats, infusion of hypertonic saline without myoinositol or infusion of myo
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。